200,000+ products from a single source!
sales@angenechem.com
85721-05-7 | 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethyl acetate
CAS No: 85721-05-7 Catalog No: AG004P9T MDL No:
Product Description
Catalog Number:
AG004P9T
Chemical Name:
2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethyl acetate
CAS Number:
85721-05-7
Molecular Formula:
C24H27ClN2O2S
Molecular Weight:
443.0014
IUPAC Name:
2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethyl acetate
InChI:
InChI=1S/C24H27ClN2O2S/c1-18(28)29-16-15-27-13-11-26(12-14-27)10-4-6-20-21-5-2-3-7-23(21)30-24-9-8-19(25)17-22(20)24/h2-3,5-9,17H,4,10-16H2,1H3/b20-6-
InChI Key:
OXAUOBQMCDIVPQ-IOXNKQMXSA-N
SMILES:
CC(=O)OCCN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(Cl)cc2
EC Number:
288-415-5
UNII:
349S2ZHF05
Properties
Complexity:
608
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1
Exact Mass:
442.148g/mol
Formal Charge:
0
Heavy Atom Count:
30
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
443.002g/mol
Monoisotopic Mass:
442.148g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
58.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.9
Literature
| Title | Journal |
|---|---|
| PBS delisting. | The Australian and New Zealand journal of psychiatry 20110601 |
| Severe laryngeal dystonia in a patient receiving zuclopenthixol 'Acuphase' and fluoxetine. | Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 20100401 |
| The potential role of zuclopenthixol acetate in the management of refractory hyperactive delirium at the end of life. | Journal of pain and symptom management 20080401 |
| Antipsychotic polypharmacy in the emergency treatment of highly aggressive schizophrenic prisoners - a retrospective study. | International journal of prisoner health 20080101 |
| Quetiapine-induced leucopenia and thrombocytopenia. | Psychosomatics 20070101 |
| Manic episode precipitated by withdrawal of hormone replacement therapy in severe hypothyroidism. | Journal of psychiatric practice 20061101 |
| Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention. | Brain and cognition 20030201 |
| Zuclopenthixol-acetate treatment in catatonic patients: the implication of iron metabolism. | European psychiatry : the journal of the Association of European Psychiatrists 20030201 |
| Use of azaperone and zuclopenthixol acetate to facilitate translocation of white-tailed deer (Odocoileus virginianus). | Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 20020601 |
| [Clopixol: new possibilities in therapy of mental disorders (a review of clinical studies)]. | Voenno-meditsinskii zhurnal 20020301 |
| Comparison of analgesic techniques for antler removal in wapiti. | The Canadian veterinary journal = La revue veterinaire canadienne 20011201 |
| Evaluation of long-term sedation in cheetah (Acinonyx jubatus) with perphenazine enanthate and zuclopenthixol acetate. | Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians 20010901 |
| Dimensionality, responsiveness and standardization of the Bech-Rafaelsen Mania Scale in the ultra-short therapy with antipsychotics in patients with severe manic episodes. | Acta psychiatrica Scandinavica 20010701 |
| Treating acquired haemophilia: an ethical conundrum. | Age and ageing 20010101 |
| Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. | International clinical psychopharmacology 19951101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.